
Antoine Cortot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2906423/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001, 411, 599-603.	13.7	5,088
2	Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology, 2011, 140, 1785-1794.e4.	0.6	1,718
3	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	6.3	996
4	Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature, 1996, 379, 821-823.	13.7	906
5	Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 1998, 115, 1405-1413.	0.6	767
6	Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Gastroenterology, 1990, 98, 811-818.	0.6	698
7	Anti- <i>Saccharomyces cerevisiae</i> mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut, 1998, 42, 788-791.	6.1	568
8	Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study. Gastroenterology, 2008, 135, 1106-1113.	0.6	549
9	European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut, 2006, 55, i16-i35.	6.1	533
10	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 1621-1628.e5.	0.6	431
11	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-l³. Journal of Experimental Medicine, 2005, 201, 1205-1215.	4.2	428
12	Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 286-292.	2.4	420
13	Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives Gut, 1994, 35, 231-235.	6.1	382
14	A Comparison of Budesonide and Mesalamine for Active Crohn's Disease. New England Journal of Medicine, 1998, 339, 370-374.	13.9	330
15	Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology, 1999, 117, 73-81.	0.6	305
16	Immunocytochemical evidence of Listeria, Escherichia coil, and Streptococcus antigens in Crohn's disease. Gastroenterology, 1995, 108, 1396-1404.	0.6	287
17	Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology, 1999, 116, 294-300.	0.6	284
18	Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut, 2014, 63, 423-432.	6.1	282

#	Article	IF	CITATIONS
19	The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study. American Journal of Gastroenterology, 2009, 104, 2080-2088.	0.2	273
20	Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. American Journal of Gastroenterology, 2002, 97, 939-946.	0.2	240
21	Incidence of inflammatory bowel disease in northern France (1988-1990) Gut, 1994, 35, 1433-1438.	6.1	215
22	Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut, 2004, 53, 843-848.	6.1	214
23	Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology, 1997, 113, 118-126.	0.6	212
24	Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut, 2005, 54, 357-363.	6.1	203
25	Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Digestive Diseases and Sciences, 1997, 42, 817-822.	1.1	201
26	Incidence, Clinical Presentation and Location at Diagnosis of Pediatric Inflammatory Bowel Disease: A Prospective Population-Based Study in Northern France (1988-1999). Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 49-55.	0.9	195
27	Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory Bowel Diseases, 2010, 16, 233-242.	0.9	187
28	Clinical characteristics of Crohn's disease in 72 families. Gastroenterology, 1996, 111, 604-607.	0.6	177
29	Natural History of Eosinophilic Gastroenteritis. Clinical Gastroenterology and Hepatology, 2011, 9, 950-956.e1.	2.4	171
30	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut, 2011, 60, 198-203.	6.1	160
31	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology, 1996, 110, 768-774.	0.6	158
32	Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy. Clinical Gastroenterology and Hepatology, 2010, 8, 1048-1055.	2.4	158
33	Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD). Digestive and Liver Disease, 2013, 45, 89-94.	0.4	157
34	European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. Gastroenterology, 1995, 109, 774-782.	0.6	156
35	Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse. Clinical Gastroenterology and Hepatology, 2009, 7, 80-85.	2.4	152
36	Anti- Saccharomyces cerevisiae Mannan Antibodies in Familial Crohn's Disease. American Journal of Gastroenterology, 1998, 93, 1306-1310.	0.2	146

#	Article	IF	CITATIONS
37	The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Alimentary Pharmacology and Therapeutics, 2011, 33, 1133-1142.	1.9	138
38	Treatment of diversion colitis by short-chain fatty acids. Diseases of the Colon and Rectum, 1991, 34, 861-864.	0.7	128
39	Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study. American Journal of Gastroenterology, 2010, 105, 1893-1900.	0.2	128
40	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut, 2014, 63, 1416-1423.	6.1	122
41	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 252-261.	1.9	111
42	Inflammatory bowel disease in spouses and their offspring. Gastroenterology, 2001, 120, 816-819.	0.6	109
43	Stressful Life Events as a Risk Factor for Inflammatory Bowel Disease Onset: A Population-Based Case–Control Study. American Journal of Gastroenterology, 2007, 102, 122-131.	0.2	109
44	The efficacy and safety of a third antiâ€TNF monoclonal antibody in Crohn's disease after failure of two other antiâ€TNF antibodies. Alimentary Pharmacology and Therapeutics, 2010, 31, 92-101.	1.9	108
45	Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease Gut, 1995, 37, 242-246.	6.1	100
46	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2063-2071.	0.9	96
47	Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. European Journal of Gastroenterology and Hepatology, 1996, 8, 229-234.	0.8	95
48	Better Outcome of Patients Undergoing Enteral Tube Feeding After Myeloablative Conditioning for Allogeneic Stem Cell Transplantation. Transplantation, 2012, 94, 287-294.	0.5	90
49	Biofeedback for the treatment of fecal incontinence. Diseases of the Colon and Rectum, 1995, 38, 393-397.	0.7	89
50	Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut, 2001, 48, 186-190.	6.1	89
51	Genetically related Escherichia coli strains associated with Crohn's disease. Gut, 2001, 48, 320-325.	6.1	87
52	Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study. Inflammatory Bowel Diseases, 2011, 17, 2144-2152.	0.9	87
53	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	2.4	80
54	A randomised placebo controlled trial of pegylated interferon in active ulcerative colitis. Gut, 2003, 52, 1728-1733.	6.1	78

#	Article	IF	CITATIONS
55	Preâ€operative management is associated with low rate of postâ€operative morbidity in penetrating Crohn's disease. Alimentary Pharmacology and Therapeutics, 2010, 32, 459-465.	1.9	78
56	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunology, 2014, 7, 589-601.	2.7	78
57	Environmental Factors in Familial Crohn's Disease in Belgium. Inflammatory Bowel Diseases, 2005, 11, 360-365.	0.9	69
58	Perioperative endoscopy of the whole small bowel in Crohn's disease Gut, 1993, 34, 647-649.	6.1	68
59	Hyperbaric oxygenation in severe perineal Crohn's disease. Diseases of the Colon and Rectum, 1995, 38, 609-614.	0.7	68
60	Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. Gastroenterologie Clinique Et Biologique, 2006, 30, 594-597.	0.9	67
61	Increased pulmonary and intestinal permeability in Crohn's disease Gut, 1992, 33, 678-682.	6.1	63
62	Anticipation in familial Crohn's disease. Gut, 1998, 42, 170-174.	6.1	63
63	Probiotics in inflammatory bowel disease: a critical review. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 805-820.	1.0	60
64	Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. American Journal of Physiology - Renal Physiology, 2014, 307, G274-G285.	1.6	60
65	Cell-Free Whey from Milk Fermented with Bifidobacterium breve C50 Used to Modify the Colonic Microflora of Healthy Subjects. Journal of Dairy Science, 1998, 81, 1229-1235.	1.4	59
66	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1476-1484.	0.9	59
67	Interferon-α in combination with corticosteroids improves systemic mast cell disease. British Journal of Dermatology, 1995, 132, 479-482.	1.4	58
68	Methotrexate in Crohn's Disease: Long-Term Efficacy and Toxicity. American Journal of Gastroenterology, 2000, 95, 1730-1734.	0.2	57
69	Mesalamine Foam Enema <i>Versus</i> Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis. American Journal of Gastroenterology, 2008, 103, 3106-3114.	0.2	56
70	Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflammatory Bowel Diseases, 2009, 15, 1044-1048.	0.9	54
71	Activated eosinophils in adult coeliac disease: evidence for a local release of major basic protein Gut, 1992, 33, 1190-1194.	6.1	49
72	Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Digestive Diseases and Sciences, 1995, 40, 2641-2646.	1.1	45

#	Article	IF	CITATIONS
73	Pneumocystis Jiroveci (Carinii) Pneumonia Following Initiation of Infliximab and Azathioprine Therapy in a Patient With Crohn's Disease. Inflammatory Bowel Diseases, 2004, 10, 436-437.	0.9	44
74	Linkage analyses of chromosome 6 loci, including HLA, in familial aggregations of Crohn disease. American Journal of Medical Genetics Part A, 1994, 52, 207-213.	2.4	42
75	Pouchitis Is Associated with Mucosal Imbalance Between Interleukin-8 and Interleukin-10. Inflammatory Bowel Diseases, 2000, 6, 157-164.	0.9	42
76	Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liege county of Belgium Gut, 1994, 35, 1316-1318.	6.1	40
77	Cap polyposis occurring in the postoperative course of pelvic surgery Gut, 1994, 35, 1670-1672.	6.1	39
78	Portomesenteric Vein Thrombosis in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 582-589.	0.9	39
79	Action of in situ nitroglycerin on upper anal canal pressure of patients with terminal constipation. Diseases of the Colon and Rectum, 1993, 36, 372-376.	0.7	38
80	Long-term Outcome After First Intestinal Resection in Pediatric-onset Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 7-14.	0.9	38
81	Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Alimentary Pharmacology and Therapeutics, 2008, 28, 984-993.	1.9	36
82	Similar IL-5, IL-3, and GM-CSF Syntheses by Eosinophils in the Jejunal Mucosa of Patients with Celiac Disease and Dermatitis Herpetiformis. Clinical Immunology and Immunopathology, 1998, 88, 14-21.	2.1	35
83	AIEC colonization and pathogenicity: Influence of previous antibiotic treatment and preexisting inflammation. Inflammatory Bowel Diseases, 2012, 18, 1923-1931.	0.9	35
84	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 533-541.	1.9	35
85	Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): No relationship with disease activity. Inflammatory Bowel Diseases, 2000, 6, 270-274.	0.9	34
86	Familial and sporadic inflammatory bowel disease: Different entities?. Inflammatory Bowel Diseases, 2000, 6, 314-320.	0.9	34
87	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Alimentary Pharmacology and Therapeutics, 2006, 24, 851-858.	1.9	32
88	Clinical predictors at diagnosis of disabling pediatric Crohn's disease. Inflammatory Bowel Diseases, 2012, 18, 2072-2078.	0.9	32
89	A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology, 2003, 124, A62.	0.6	31
90	Mapping of inflammatory bowel disease in northern France: Spatial variations and relation to affluence. Inflammatory Bowel Diseases, 2010, 16, 807-812.	0.9	30

#	Article	IF	CITATIONS
91	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARÎ ³ . Carcinogenesis, 2013, 34, 2580-2586.	1.3	30
92	Colonic Inflammation in Mice Is Improved by Cigarette Smoke through iNKT Cells Recruitment. PLoS ONE, 2013, 8, e62208.	1.1	30
93	Bipolar electrocoagulation treatment for hemorrhagic radiation injury of the lower digestive tract. Gastrointestinal Endoscopy, 1991, 37, 492-493.	0.5	28
94	Functional assessment of coloanal anastomosis with reservoir and excision of the anal transition zone. Diseases of the Colon and Rectum, 1991, 34, 967-972.	0.7	27
95	Familial and Sporadic Inflammatory Bowel Disease: Different Entities?. Inflammatory Bowel Diseases, 2000, 6, 314-320.	0.9	26
96	Antibiotics in Crohn's disease. Gut, 2001, 48, 647-647.	6.1	26
97	Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. American Journal of Gastroenterology, 2002, 97, 649-653.	0.2	26
98	Endoscopic palliation for inoperable malignant dysphagia: long term follow up Gut, 1992, 33, 1602-1607.	6.1	24
99	Pneumocystis jiroveci (carinii) Pneumonia After Initiation of Infliximab and Azathioprine Therapy in a Patient with Crohn's Disease. Inflammatory Bowel Diseases, 2005, 11, 618-620.	0.9	24
100	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut, 2017, 66, 1912-1917.	6.1	24
101	Efficacy of Diosmectite (Smecta) [®] in the Treatment of Acute Watery Diarrhoea in Adults: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study. Gastroenterology Research and Practice, 2011, 2011, 1-8.	0.7	23
102	Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case–Control and Cohort Studies. Clinical Gastroenterology and Hepatology, 2015, 13, 1405-1415.e1.	2.4	23
103	Eosinophilic Enteritis. Digestive Diseases, 2015, 33, 183-189.	0.8	22
104	Transdermal Nicotine Decreases Mucosal IL-8 Expression but Has No Effect on Mucin Gene Expression in Ulcerative Colitis. Inflammatory Bowel Diseases, 1999, 5, 174-181.	0.9	20
105	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. Journal of Crohn's and Colitis, 2017, 11, 1326-1334.	0.6	19
106	What are the major arguments in favour of the genetic susceptibility for inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2003, 15, 587-592.	0.8	18
107	Familial Crohn's Disease in Belgium. Journal of Clinical Gastroenterology, 2007, 41, 583-590.	1.1	18
108	Stevens–Johnson syndrome with sulfasalazine treatment: Report of two cases. Journal of Crohn's and Colitis, 2011, 5, 457-460.	0.6	18

#	Article	IF	CITATIONS
109	Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. European Journal of Gastroenterology and Hepatology, 1999, 11, 1113-1120.	0.8	17
110	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. Journal of Crohn's and Colitis, 2016, 11, jjw151.	0.6	17
111	Anti-Neutrophil Cytoplasmic Auto-Antibodies (ANCA) in Patients with Ulcerative Colitis (UC): Influence of Disease Activity and Familial Study. Advances in Experimental Medicine and Biology, 1993, 336, 515-518.	0.8	15
112	Nitroglycerinin situ reduces upper anal canal pressure. Digestive Diseases and Sciences, 1992, 37, 155-155.	1.1	14
113	Growth hormone enhances fat-free mass and glutamine availability in patients with short-bowel syndrome: an ancillary double-blind, randomized crossover study , ,. American Journal of Clinical Nutrition, 2014, 100, 850-858.	2.2	14
114	Oxidative and synthetic functions of n-butyrate in colonocytes. Diseases of the Colon and Rectum, 1992, 35, 511-512.	0.7	12
115	IgM-specific measles-virus antibody in families with a high frequency of Crohn's disease. Lancet, The, 1995, 346, 967.	6.3	12
116	Space-time clusters of Crohn's disease in northern France. Zeitschrift Fur Gesundheitswissenschaften, 2013, 21, 497-504.	0.8	12
117	Post-operative recurrence of Crohn's disease after definitive stoma: an underestimated risk. International Journal of Colorectal Disease, 2017, 32, 453-458.	1.0	11
118	Épidémiologie et facteurs de risque des maladies inflammatoires chroniques de l'intestin. Bulletin De L'Academie Nationale De Medecine, 2007, 191, 1105-1123.	0.0	11
119	Chronic pancreatitis: a complication of sarcoidosis?. European Journal of Gastroenterology and Hepatology, 1996, 8, 1125-1127.	0.8	10
120	Virus Serology in Familial Crohn Disease. Scandinavian Journal of Gastroenterology, 2000, 35, 403-407.	0.6	10
121	Efficacy of sacral nerve stimulation for poor functional results of J-pouch ileoanal anastomosis. Techniques in Coloproctology, 2014, 18, 355-360.	0.8	10
122	Infectious agents and Crohn's disease. Clinical Microbiology and Infection, 1999, 5, 601-604.	2.8	9
123	Deglycosylation of α1-proteinase inhibitor is impaired in the faeces of patients with active inflammatory bowel disease (Crohn's disease). Clinical Science, 1991, 80, 517-523.	1.8	8
124	Differentiation and identification of human faecal anaerobic bacteria producing β-galactosidase (a new) Tj ETQq	0 0 0 rgBT 0.7	Overlock 10
125	Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease. Gastroenterology, 2003, 124, A192-A193.	0.6	8

¹²⁶Mixed Adenocarcinoid Tumor and Crohn's Disease. Journal of Clinical Gastroenterology, 1998, 26,
353-354.1.18

#	Article	IF	CITATIONS
127	Effect of intrajejunal elemental diet perfusion on jejunal secretion of immunoglobulins, albumin, and hyaluronan in man Gut, 1992, 33, 44-47.	6.1	7
128	Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis Gut, 1995, 37, 132-135.	6.1	6
129	Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). Gastroenterology, 1998, 114, A958-A959.	0.6	5
130	Azathioprine (AZA) for ulcerative coltis: A retrospective multicente study on 131 patients. Gastroenterology, 2001, 120, A625-A626.	0.6	5
131	Invasive ability of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). Gastroenterology, 2000, 118, A342.	0.6	4
132	The Importance of Familial Clusterings in Crohn's Disease. Inflammatory Bowel Diseases, 2001, 7, 170-173.	0.9	4
133	Severe acute pancreatitis following laser treatment of periampullary villous adenoma. Digestive Diseases and Sciences, 1993, 38, 382-383.	1.1	2
134	Intestinal involvement in sarcoidosis. Gastroenterology, 1993, 104, 947.	0.6	2
135	Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. Clinical and Experimental Immunology, 1996, 104, 293-296.	1.1	2
136	A fulminant colitis index greater or equal to 8Âis not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroenterologie Clinique Et Biologique, 2010, 34, 612-617.	0.9	2
137	Early Surgery is Not Associated With Poor Prognosis in Pediatric Crohn's Disease: A Population-Based Study. Gastroenterology, 2011, 140, S-38.	0.6	2
138	Stratification of Crohn's disease by anti Saccharomyces cerevisiae mannan antibodies (ASCA) and antineutrophil cytoplasmic antibodies (ANCA). Gastroenterology, 1998, 114, A950.	0.6	1
139	Mesenteric obesity in Crohn's disease (CD). Gastroenterology, 1998, 114, A989.	0.6	1
140	Low ileal IL-10 mRNA levels may predict endoscopic recurrence after surgery in a subgroup of patients with Crohn's disease (CD). Gastroenterology, 1998, 114, A1038.	0.6	1
141	114 The Changing Pattern of Crohn's Disease Incidence According to Age in Northern France: A Constant Increase in the 0-19 Year's Age Group (1988-2005). Gastroenterology, 2009, 136, A-20.	0.6	1
142	Mo1899 Evaluation and Long-Term Benefit of Deep Remission in Crohn's Disease Patients Treated With Infliximab. Gastroenterology, 2016, 150, S810-S811.	0.6	1
143	Molecular form of faecal alpha 1 antitrypsin in patients with Crohn's disease Gut, 1992, 33, 572-572.	6.1	0
144	Endoscopic Laser Treatment for Rectosigmoid Villous Adenoma: Factors Affecting the Results. Canadian Journal of Gastroenterology & Hepatology, 1992, 6, 301-307.	1.8	0

#	Article	IF	CITATIONS
145	Low prevalence of gastric infection by Helicobacter pylori (HP) during long term treatment of esophagitis with omeprazole. Gastroenterology, 1995, 108, A60.	0.6	0
146	Influence of the degree of severity of fundic gastritis on serum gastrin concentration and ECL cell density in controls and during prolonged treatment with antisecretory drugs. Gastroenterology, 1995, 108, A83.	0.6	0
147	Visual evoked potentials, electroretinogram and neuropsychological evaluation in malnutrition. Gastroenterology, 1995, 108, A721.	0.6	0
148	Serosal vascular lesions in Crohn's disease. Gastroenterology, 1995, 108, A808.	0.6	0
149	Density of fundic ECL cells during long term treatment of reflux esophagitis by omeprazole or histamine H2-receptor antagonists. Gastroenterology, 1995, 108, A266.	0.6	0
150	No bacteria detected by PCR in mesenteric lymph nodes from patients with Crohn's disease (CD). Gastroenterology, 1998, 114, A944-A945.	0.6	0
151	Is endoscopic ultrasonography helpful before ERCP in the management of patients at risk of biliary obstruction?. Gastroenterology, 1998, 114, A530.	0.6	0
152	An evaluation of the effects of budesonide and mesalamine on the clinical condition of patients with active Crohn's disease. Gastroenterology, 2000, 118, A782.	0.6	0
153	A comparison of the effect of budesonide and mesalamine on quality-of-life in patients with active Crohn's disease. Gastroenterology, 2000, 118, A783.	0.6	0
154	Low ileal IL-10 mRNA levels predict endoscopic recurrence in patients operated on for Crohn's disease (CD). Gastroenterology, 2000, 118, A108-A109.	0.6	0
155	Effect of switching to budesonide on the quality of life of patients with steroid-dependent Crohn's disease. Gastroenterology, 2001, 120, A748.	0.6	0
156	Safety of switching systemic steroids to budesonide modified-release capsules in steroid-dependent patients with inactive Crohn's disease. Gastroenterology, 2001, 120, A749.	0.6	0
157	Increased incidence of crohn's disease in children in Northern France. Results of a prospective population-based study (1988È 999). Gastroenterology, 2003, 124, A208.	0.6	0
158	Echoendoscopy modifies classical predictive criteria of a biliary origin of acute pancreatitis: Prospective multicentre french study. Gastroenterology, 2003, 124, A84.	0.6	0
159	Thiopurine S-methyltransferase deficiency associated with a novel mutation. Inflammatory Bowel Diseases, 2010, 16, 1821-1822.	0.9	0
160	S2002 Predictors of Poor Outcome in Pediatric Crohn's Disease. Gastroenterology, 2010, 138, S-298-S-299.	0.6	0
161	Clinical Course of Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis: Results of a National Multicentre Study. Gastroenterology, 2011, 140, S-776.	0.6	0
162	Mo1900 Combination Therapy With Infliximab and Methotrexate Does Not Improve Crohn's Disease Outcome and Infliximab Tolerance Compared to Infliximab Therapy Alone. Gastroenterology, 2016, 150, S811.	0.6	0

#	Article	IF	CITATIONS
163	Mo1898 Continuation or Switch to Another Anti-TNFα After Intestinal Resection in Crohn's Disease Patients Previously Exposed to Anti-TNFα?. Gastroenterology, 2016, 150, S810.	0.6	0